Aurinia Pharmaceuticals (AUPH) Gross Profit (2020 - 2026)

Aurinia Pharmaceuticals (AUPH) has 7 years of Gross Profit data on file, last reported at $71.2 million in Q1 2026.

• For the quarter ending Q1 2026, Gross Profit rose 32.12% year-over-year to $71.2 million; the trailing twelve-month figure through Mar 2026 stood at $267.7 million (up 22.67% YoY), and the FY2025 full-year result was $250.4 million, up 21.03% from the prior year.
• Gross Profit for Q1 2026 stood at $71.2 million, up from $68.3 million in the prior quarter.
• Across five years, Gross Profit topped out at $71.2 million in Q1 2026 and bottomed at $21.4 million in Q1 2022.
• The 5-year median for Gross Profit is $48.3 million (2024), against an average of $48.1 million.
• The widest annual swing landed in 2022, when Gross Profit soared 2367.55%; it then dropped 10.47% in 2023.
• A 5-year view of Gross Profit shows it stood at $27.1 million in 2022, then surged by 46.64% to $39.7 million in 2023, then soared by 36.81% to $54.3 million in 2024, then advanced by 25.78% to $68.3 million in 2025, then increased by 4.22% to $71.2 million in 2026.
• The last three Gross Profit figures came in at $71.2 million (Q1 2026), $68.3 million (Q4 2025), and $65.3 million (Q3 2025), per Business Quant data.

Peer Comparison